摘要:

AbstractContinuous chemotherapy was administered to 82 patients through the hepatic artery via Infusaid pumps. In order to obtain a primary status and to evaluate the success of therapy, the perfusion patterns of the liver and of the existing tumor masses in the liver were estimated by conducting arterial angiocomputed tomographies (AACTs) immediately after pump implantation of every 3 months thereafter. In 70% of the patients, findings showed both liver lobes to be homogeneously perfused, 24% demonstrated distinct inhomogeneities. The response of the latter cases should depend primarily on the efficacy of the administered cytostatic agent. Six percent of the patients showed selective perfusion of either the left or right hepatic lobe. In these cases, only me perfused liver regions exhibited stable disease or regression of the metastases, whereas the metastases of the nonperfused regions progressed. At 3-month follow-up, the majority of the patients (50–57%) showed homogeneous hepatic perfusion. Inhomogeneities were found in 26–36% of the patients, 12 patients demonstrated incomplete perfusion. There was no association between the perfusion patterns of the metastases or of the prechemotherapeutic liver involvement and the response of the metastases to regional chemotherapy. In regional chemotherapy, liver perfusion should be controlled both intraoperatively or directly postoperatively and during therapy.

ISSN:0735-7907    

DOI:10.3109/07357909009017557

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractA Phase I trial of three carboplatin-based combination chemotherapy regimens was conducted. These included: carboplatin plus vindesine; carboplatin, vindesine, plus bleomycin; and, carboplatin plus vinblastine. Carboplatin was administered every 28 days as an intravenous bolus. The initial dose was 150 mg/m2and doses were escalated by 50 mg/m2in each successive group of patients. Vindesine was given at a dose of 3 mg/m2weekly for 5 doses, then every other week thereafter. Bleomycin, 10 units/m2IV bolus, was followed by 10 units/m2/day infusion for 4 days (3–7 and 31–35). Vinblastine was given at 5 mg/m2every other week. Doses of vindesine, vinblastine, and bleomycin were not escalated. The maximum tolerated dose (MTD) of the carboplatin, vindesine bleomycin regimens was reached at a carboplatin dose of 250 mg/m2and the MTD was influenced by the weekly vindesine in the initial 4 weeks of therapy. The MTD of the carboplatin and vinblastine regimen was reached at a carboplatin dose of 500 mg/m2. Dose-limiting toxicity of all three regimens was leukopenia. Although nonhematological toxicity of the carboplatin and vinblastine regimen included peripheral neuropathy and emesis, therapy was easily administered in an outpatient setting. The recommended Phase II dose of carboplatin is 450 mg/m2in combination with vinblasrine at this dose and schedule for previously untreated patients. Twelve patients demonstrated major responses with the various regimens including 5 of 24 patients with adenocarcinoma of the upper gastrointestinal tract.

ISSN:0735-7907    

DOI:10.3109/07357909009017558

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractTwenty patients with refractory multiple myeloma were treated with methylglyoxalbis(guanylhydrazone) (MGBG), an inhibitor of polyamine synthesis. MGBG 500 mg/m2was administered on days 1 and 8, and then every 14 days. The dose was escalated to 600 mg/m2on day 22, as tolerated. Of 14 evaluable patients, none met ECOG criteria for an objective response. The major toxicity was hematologic and related infections. MGBG demonstrated insufficient activity in the treatment of refractory multiple myeloma to warrant further study.

ISSN:0735-7907    

DOI:10.3109/07357909009017559

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractMethods of assessing and reporting toxic reactions induced by therapy, particularly chemotherapy, need improvements. Accurate and reliable reporting of therapyinduced toxicity will be necessary for quality clinical research including drug development and for implementation of complex multìmodality treatments, currently, however, the extent and quality of reporting of toxic reactions vary widely. Whereas standard and widely accepted criteria have been established for assessing and reporting therapeutic response, no such criteria exist for toxicity. We have developed comprehensive criteria for assessing and reliably reporting toxic reactions. We have reduced the degree of subjectivity in assigning grades by using primarily objective methods. An attempt has been made to standardize the“morbidity impact”of each toxicity grade irrespective of the organ system involved.

ISSN:0735-7907    

DOI:10.3109/07357909009017560

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractGanglioside composition of human melanoma was correlated with sensitivity of melanoma to antitumor treatment with chemotherapeutic agents and radiation. The cytotoxic effect of each treatment was evaluated on 16 melanoma cell lines using the human tumor colony-forming assay. Ganglioside fractions were extracted and purified from each cell line and analyzed for the four major gangliosides in melanoma (GM3, GM2, GD3, and GD2) by thin-layer chromatography (TLC) and TLC scanner. GD2 content positively correlated with sensitivity to radiation (r =0.753, p<0.001) and vincristìne (r =0.779, p<0.001). In contrast, GM3 content inversely correlated with sensitivity to radiation (r = -0.658, p<0.01) and vincristìne (r = -0.692,<0.01). The gangliosides GD3 and GM2 were shown to have no significant correlation with any of these treatments.

ISSN:0735-7907    

DOI:10.3109/07357909009017561

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

摘要:

AbstractThe major finding of this work is that there are specific restriction enzyme inhibitors present in“purified”tumor DNA which cause partial digestion patterns when tumor DNA is digested by standard procedures with any of three commonly employed restriction enzymes (Hind Ill, Kpnl, Xbal). These aberrant patterns are not seen when DNA of cell lines derived from these tumors is digested. Thus, when working with tumor DNA these restriction enzymes should be used with caution.

ISSN:0735-7907    

DOI:10.3109/07357909009017562

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009017563

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009017564

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009017565

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor

ISSN:0735-7907    

DOI:10.3109/07357909009017566

出版商:Taylor&Francis    

年代:1990

数据来源: Taylor